Angiotech Looks Beyond Stents To Other Anti-Scarring Treatments
This article was originally published in The Gray Sheet
Executive Summary
Angiotech will begin studies evaluating paclitaxel for elbow and knee injuries in an effort to diversify its product offerings starting in the third quarter